![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.135 | -2.91% | 4.51 | 4.41 | 4.99 | 4.53 | 4.51 | 4.53 | 189,892 | 11:53:49 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.51 | 9.35M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/7/2020 10:04 | The question to ask yourselves is what is the value of this result. If you think under £150m then sell. If £500m then hold | coyscoys | |
20/7/2020 10:04 | SNG gone from a backwater investment to now being my No.1 by value! | ![]() freedosh | |
20/7/2020 10:03 | looks like funds moving into NFX, news imminent on pipeline products... | ![]() pre | |
20/7/2020 10:03 | Now we derampers from here and LSE, u can be in or out but in the end we should be pleased that it going to help those suffering and those who might get it, in few months times we will have winter approaching, so all companies large or small helping to find a cure or treatment be help to the world. It's simple as that. | ![]() amrishbhim | |
20/7/2020 10:01 | Here we go next leg up | slinkyj | |
20/7/2020 10:01 | This makes up for me selling TILS too early at 86p. ??? | ![]() dovey21 | |
20/7/2020 10:01 | Will be taken over .AZN I would expect | ![]() fidra | |
20/7/2020 10:00 | Well done guys. Profits into HEMO for another multi bagger | ![]() justaman | |
20/7/2020 09:59 | COPD worth billions alone will more than likely be successful also which was put on hold for the Cv19 trials and obviously showed promise as it was for them to go for the Cv19 trails. Writing is on the wall. | tidy 2 | |
20/7/2020 09:58 | Hopefully there'll be a lot more interest once US markets open... | ![]() sikhthetech | |
20/7/2020 09:58 | Anyone else struggling to sell on aj bell? | ![]() rmc100 | |
20/7/2020 09:57 | In at £1 out at £1.52 Thank you - lunch I think. | ![]() niggle | |
20/7/2020 09:57 | Can someone drop Donald Trump a tweet about this. Forget hydroxychloroquine, forget 'light inside the body', forget 'ingesting disinfectant solution', this is the real deal. Tremendous, this is going to make billions and millions of people better and the virus is just going to disappear, just disappear folks...... | spqstrader | |
20/7/2020 09:57 | finnCap: "Synairgen (SNG): Corp COVID-19 treatment â" positive Phase II data Synairgen released very positive results from its Phase II trial of SNG001 in hospitalised COVID-19 patients â" a 79% reduction in patients developing severe disease or death, with those on SNG001 more than twice as likely to recover over the treatment period than those on placebo. Both were statistically significant. Valuing the COVID-19 opportunity is nigh on impossible; however, we upgrade our target price to 360p but recognise that this could go substantially higher, based on upcoming discussions with regulators, which should clarify the route to market and the potential for buying SNG001 ahead of the winter 2020 flu season and the possibility of a second wave of COVID-19." | tidy 2 | |
20/7/2020 09:55 | opps - am out - | ![]() tomboyb | |
20/7/2020 09:54 | I'll keep my eye on itCheersThe MICE | ![]() catchingmice | |
20/7/2020 09:54 | Next leg to 200p here we come ... | ![]() g2theary | |
20/7/2020 09:53 | Next MONSTER Covid 19 gem with Phase 3 RESULTS in Q4 =10++BAGGER (CTIC) MCap $105 M / Cash $81 M/ 2x PHASE 3 Drugs with first results in Q4 for the Covid 19 Drug / UNDISCOVERED gem = Next UNDISCOVERED 10++ BAGGER hxxps://assets.walls | bioking |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions